Ftse Mib
33.414,56
0,46%
DAX
19.626,45
1,05%
S&P 500
6.032,38
0,56%
NASDAQ
19.218,17
0,83%
Bitcoin
96.862,81
-0,64%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Synta Pharmaceuticals Corp. (MM) (SNTA) Synta Pharmaceuticals Corp. (MM) (SNTA) Notizie

SNTA

Synta Pharmaceuticals Corp. (MM) (SNTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNTA
DataOraFonteTitoloSimboloCompagnia
29/07/201621:13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
26/07/201623:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
26/07/201621:38Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
22/07/201623:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
22/07/201617:30GlobeNewswire Inc.Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH CompanyNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
21/07/201622:17Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
20/07/201622:04Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/07/201622:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
01/07/201613:35PR Newswire (US)Why Investors Have These Biotech Stocks on Their Radar? - Synta Pharma, Idera Pharma, Threshold Pharma, and Viking Therapeuti...NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/06/201622:15Business WireSynta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal PharmaceuticalsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/06/201622:03Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (definitive) (defm14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/06/201613:00Business WireSynta Pharmaceuticals to Present at Upcoming Investor Conferences in JuneNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
27/05/201614:20PR Newswire (US)Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat BiologicsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
19/05/201612:03Edgar (US Regulatory)Proxy Statement - Merger or Acquistion (preliminary) (prem14a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
29/04/201614:33Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
28/04/201612:12Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
14/04/201613:00Business WireSynta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH CompanyNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
13/11/201517:22Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
05/11/201523:20Business WireSynta Reports Third Quarter 2015 Financial ResultsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
21/10/201501:30Business WireSynta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung CancerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/10/201513:30Business WireSynta Pharmaceuticals Announces Formation of Expert Oncology PanelNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
09/09/201514:00Business WireSynta Names Alan C. Rigby, Ph.D. Chief Scientific OfficerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
08/09/201514:00Business WireSynta Announces Presentations at the 16th Annual World Conference on Lung CancerNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/09/201522:01Business WireSynta to Participate in FBR Second Annual Healthcare ConferenceNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/08/201518:08Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
06/08/201513:00Business WireSynta Reports Second Quarter 2015 Financial ResultsNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
30/07/201522:01Business WireSynta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
23/06/201514:00Business WireSynta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition & Immune Checkpoint Blockade for Ca...NASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
16/06/201522:01Business WireSynta to Participate in Upcoming Investor ConferencesNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
02/06/201515:00Business WireSynta Announces Ganetespib Program UpdatesNASDAQ:SNTASynta Pharmaceuticals Corp. (MM)
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNTA

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
BAMI
Banco BPM
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
MONC
Moncler
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
MB
Mediobanca Banca di Cred...
BIT
G
Generali
BIT
BPE
Bper Banca
BIT
SPM
Saipem
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network